Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MRKAd5 HIV-1 gag vaccine (V520)
MRKAd5 HIV-1 gag vaccine · 1 trial · 1 indication
Serious and non serious clinical (systemic and injection-site AEs), and laboratory AEs were collected. Systemic and laboratory AEs reflect any unfavorable \& unintended change in the structure, function, or chemistry of the body. Injection-site AEs include any swelling, redness, pain or tenderness at the injection site. Vaccine-related AEs are those determined by the investigator to be possibly, probably, or definitely related to the administration of the vaccine.
| Arm | Type | Description |
|---|---|---|
| MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose | EXPERIMENTAL | Participants administered MRKAd5 HIV-1 gag vaccine 1x10\^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26. |
| MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose | EXPERIMENTAL | Participants were to be administered MRKAd5 HIV-1 gag 1x10\^10 vp/dose (V520) on Day 1, Week 4, and Week 26. Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10\^10 vp/dose. |
| Placebo | EXPERIMENTAL | Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26. |
| Open Label Tetanus and Diptheria Toxoids Adsorbed | SHAM_COMPARATOR | Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only. Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group. |
| Name | Type | Description |
|---|---|---|
| MRKAd5 HIV-1 gag vaccine (V520) | BIOLOGICAL | 3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26 |
| Comparator: Placebo | BIOLOGICAL | 1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26 |
| Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed | BIOLOGICAL | 0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only |
Inclusion Criteria: * Subject who is of reproductive potential agrees to use a acceptable method of birth control through week 52 of the study Exclusion Criteria: * Subject weighs less than 110 lbs. * Subject has received treatment for hepatitis C virus infection in the 3 months before enrollment...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
MRKAd5 HIV-1 gag vaccine is an investigational vaccine developed by Merck & Company, Inc. (ticker: MRK). It is a vaccine candidate that has been studied in a Phase 1 clinical trial in subjects with chronic hepatitis C. The vaccine is also known as V520.
MRKAd5 HIV-1 gag vaccine has been studied in a Phase 1 clinical trial for use in subjects with chronic hepatitis C. It is an investigational vaccine and is not approved for any indication.
MRKAd5 HIV-1 gag vaccine is developed by Merck & Company, Inc., which trades under the ticker symbol MRK.
MRKAd5 HIV-1 gag vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA for any indication.
MRKAd5 HIV-1 gag vaccine has been evaluated in one completed Phase 1 clinical trial, NCT00857311, titled "MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022)." The trial enrolled 17 participants and was randomized, double-blind, and sham-controlled.
Yes, MRKAd5 HIV-1 gag vaccine is also known as V520. The alternative name V520 appears in the trial identifier for the Phase 1 study NCT00857311.